Published 6 days ago • loading... • Updated 6 days ago

Astrazeneca in ASCO 2025: More than 80 Abstracts, 20 Drugs and 2 Plenary

Summary by redaccionmedica.com

AstraZeneca continues to advance in its ambition to eliminate cancer as a cause of death, and demonstrates this with the presentation of new data from its diverse and consolidated portfolio of products during the annual congress of the American Society of Clinical Oncology (ASCO), to be held from 30 May to 3 June 2025. In this event, the company will show more than 80 abstracts that gather results from 20 drugs, both approved and developing. Amo…

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All

Left

Center

Right

redaccionmedica.com

Astrazeneca in ASCO 2025: More than 80 Abstracts, 20 Drugs and 2 Plenary

6 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated6 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

redaccionmedica.com broke the news in 6 days ago on Monday, May 26, 2025.

Sources are mostly out of (0)

Astrazeneca in ASCO 2025: More than 80 Abstracts, 20 Drugs and 2 Plenary

1 Articles

1 Articles

Astrazeneca in ASCO 2025: More than 80 Abstracts, 20 Drugs and 2 Plenary

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics